No annual revenue total was found in Citius Oncology, Inc.'s SEC filings.
Citius Oncology, Inc. (CTOR) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $16.6 million in cash and investments and $6.4 million in total debt.
Revenue
—
Net income (TTM)
$-46.06M
Operating cash flow
$-5.49M
-4446.6% vs prior year
Free cash flow
—
EPS (TTM)
$-0.49
Dividend per share
None
Shares outstanding
84.80M
+18.5% vs prior year
Net cash
$10.15M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CTOR (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- DE
- Headquarters
- Cranford, NJ
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1851484
- Former names
- TenX Keane Acquisition (until Aug 5, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Sep 30, 2025 |
FY 2024 Sep 30, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
|---|---|---|---|---|
| Operating income | -$23.5M | — | -$1.0M | -$138,115 |
| Net income | -$24.8M | -$21.1M | $2.4M | $380,811 |
| Diluted EPS | -$0.34 | -$0.31 | $0.27 | $0.12 |
| Operating cash flow | -$5.5M | $126,353 | -$601,304 | -$47,968 |
| Total assets | $100.9M | $84.4M | $72.6M | $68.2M |
| Total liabilities | $56.1M | $38.2M | — | — |
| Stockholders' equity | $44.9M | $46.1M | -$2.0M | $345,508 |
| Cash and investments | $3.9M | $112 | $72.6M | $68.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 26, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Other events
|
Oct 23, 2026 | Oct 19, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Sep 29, 2026 | Sep 29, 2026 |
| ARS | Annual report to shareholders | Aug 26, 2026 | Sep 30, 2025 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
All 268 Citius Oncology, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.